Sandoz net sales of USD 2.3 billion were down 5% (-4% cc) in the fourth quarter, impacted by additional competition to enoxaparin. Enoxaparin, our first generic blockbuster, achieved sales of USD 1.0 billion in 2011 (USD 225 million in the fourth quarter).
I've given up trying to understand how these professional "analysts" model revenue for MNTA. With the new run rate of $900 M - $1.1 B in mLovenox sales, my Excel spreadsheet calculates a MNTA revenue at $260 M for 2012.
Assumptions are as follows: Operating Margins at 68% NVS mLov revenue at $250 M/quarter